Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.

被引：0

作者：

Wang, Jing ^{[1
]}

Li, Siqi ^{[1
]}

Jiang, Hao ^{[1
]}

Chang, Ying-Jun ^{[1
]}

Zhao, Xiao-Su ^{[1
]}

Jia, Jin-Song ^{[1
]}

Zhu, Xiao-Lu ^{[1
]}

Gong, Li-Zhong ^{[1
]}

Liu, Xiao-Hong ^{[1
]}

Yu, Wen-Jing ^{[1
]}

Huang, Xiao-Jun ^{[1
]}

机构：

[1] Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Beijing Key Lab Hem, Beijing, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7052

引用

页数：1